Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study

References

• LozanoR, NaghaviM, ForemanK, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; 2020.
   Google Scholar
• KimC, YooKH, RheeCK, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis. 2014;18(6):737–743. doi:10.5588/ijtld.13.063424903947
   PubMed Web of Science ®Google Scholar
• TanWC, NgTP. COPD in Asia: where east meets west. CHEST. 2008;133(2):517–527. doi:10.1378/chest.07-113118252918
   PubMed Web of Science ®Google Scholar
• ZhongN, WangC, YaoW, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–760. doi:10.1164/rccm.200612-1749OC17575095
   PubMed Web of Science ®Google Scholar
• MathersCD, LoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• YooKH, KimYS, SheenSS, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology. 2011;16(4):659–665. doi:10.1111/res.2011.16.issue-421342331
   PubMed Web of Science ®Google Scholar
• FangL, GaoP, BaoH, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430. doi:10.1016/S2213-2600(18)30103-629650407
   PubMed Web of Science ®Google Scholar
• ZhuB, WangY, MingJ, ChenW, ZhangL. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353–1364. doi:10.2147/COPD29731623
   PubMed Web of Science ®Google Scholar
• TashkinDP, CelliB, SennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• BabuKS, MorjariaJB. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther Adv Chronic Dis. 2017;8(4–5):81–91. doi:10.1177/204062231770082228491268
   PubMed Web of Science ®Google Scholar
• FeldmanG, MaltaisF, KhindriS, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730. doi:10.2147/COPD.S10249427103795
   PubMed Web of Science ®Google Scholar
• Incruse Ellipta® (umeclidinium bromide) [summary of product characteristics]. Dublin, Ireland: GlaxoSmithKline; 2019.
   Google Scholar
• Incruse Ellipta® (umeclidinium bromide) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2017.
   Google Scholar
• DonohueJF, AnzuetoA, BrooksJ, MehtaR, KalbergC, CraterG. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970–979. doi:10.1016/j.rmed.2012.03.01222498110
   PubMed Web of Science ®Google Scholar
• DonohueJF, NiewoehnerD, BrooksJ, O’DellD, ChurchA. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78. doi:10.1186/1465-9921-15-7825015176
   PubMed Web of Science ®Google Scholar
• ZhengJ, ZhongN, NewlandsA, ChurchA, GohAH. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2015;10:1753–1767.26366068
   PubMed Web of Science ®Google Scholar
• KimKY, MiravitllesM, SliwinskiP, et al. Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study. Int J Chron Obstruct Pulmon Dis. 2019;14:1595–1601.31440042
   PubMed Web of Science ®Google Scholar
• MartinA, BadrickE, MathurR, HullS. Effect of ethnicity on the prevalence, severity, and management of COPD in general practice. Br J Gen Pract. 2012;62(595):e76–e81. doi:10.3399/bjgp12X62512022520773
   PubMed Web of Science ®Google Scholar
• WedzichaJA, ZhongN, IchinoseM, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis. 2017;12:339–349. doi:10.2147/COPD.S12505828176893
   PubMed Web of Science ®Google Scholar
• DonohueJF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. doi:10.1081/COPD-20005337717136971
   PubMedGoogle Scholar
• DecramerM, MaltaisF, FeldmanG, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393–399. doi:10.1016/j.resp.2012.08.02223026438
   PubMed Web of Science ®Google Scholar
• TrivediR, RichardN, MehtaR, ChurchA. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81. doi:10.1183/09031936.0003321323949963
   PubMed Web of Science ®Google Scholar
• DonohueJF, Maleki-YazdiMR, KilbrideS, MehtaR, KalbergC, ChurchA. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
   PubMed Web of Science ®Google Scholar
• FukuchiY, FernandezL, KuoHP, et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology. 2011;16(5):825–835. doi:10.1111/j.1440-1843.2011.01982.x21539680
   PubMed Web of Science ®Google Scholar
• WangC, SunT, HuangY, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis. 2015;10:57–68. doi:10.2147/COPD.S7265025609940
   PubMed Web of Science ®Google Scholar
• SedgwickP, GreenwoodN. Understanding the Hawthorne effect. BMJ. 2015;351:h4672. doi:10.1136/bmj.h467226341898
   PubMed Web of Science ®Google Scholar